← Leaderboards
Jonathan Brody
Thomas Jefferson University
$5,162,616
Attributed
$12,021,994
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,021,994 · 6
By mechanism
U01$7,998,169 · 2
R01$3,283,473 · 2
R21$740,352 · 2
Top collaborators
- Rosalie C Sears9 shared
- Lisa M Coussens5 shared
- Emek Demir5 shared
- Elana Fertig2 shared
- Jordan M Winter2 shared
- Laura Delong Wood2 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Jordan M Winter$3,794,444
- Wayne E Childers$697,333
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasMalignant NeoplasmsTumorMolecularSamplingDna RepairPharmaceutical PreparationsPancreatic Ductal AdenocarcinomaTargeted TreatmentPhenotypeCommunitiesMutationIn VivoClinical TrialsResponseDrug ResistanceResistanceBaseBiologyMultidisciplinaryNeoplastic CellCellsAffectDrug Sensitivity
Grant awards (19)
An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals$4,014,885
U01 · FY2025 · CA
Optimizing anti-wild-type IDH1 therapy in pancreatic cancer$661,060
R01 · FY2025 · CA
An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals$1,035,138
U01 · FY2024 · CA
Optimizing anti-wild-type IDH1 therapy in pancreatic cancer$690,929
R01 · FY2024 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$546,688
U01 · FY2023 · CA
Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers$158,826
R21 · FY2023 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$547,032
U01 · FY2022 · CA
Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers$210,688
R21 · FY2022 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$714,330
U01 · FY2021 · CA
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer$360,416
R01 · FY2021 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$560,027
U01 · FY2020 · CA
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer$426,326
R01 · FY2020 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$580,069
U01 · FY2019 · CA
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer$346,460
R01 · FY2019 · CA · contact PI
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer$27,929
R01 · FY2019 · CA · contact PI
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer$372,748
R01 · FY2018 · CA · contact PI
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer$397,605
R01 · FY2017 · CA · contact PI
Utilizing HuR to optimize the treatment of pancreatic cancer$168,563
R21 · FY2015 · CA · contact PI
Utilizing HuR to optimize the treatment of pancreatic cancer$202,275
R21 · FY2014 · CA · contact PI